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Abstract
Introduction: This study assessed the utility of cerebrospinal fluid (CSF) neurofilament
light (NfL) in Alzheimer’s disease (AD) diagnosis, its association with amyloid and tau
pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accu-
mulation.
Methods:CSFNfL concentrationwasmeasured in 221 participants from theAustralian
Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL).
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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Results: CSF NfL levels as well as NfL/amyloid 𝛽 (A𝛽42) were significantly elevated in
ADcompared to healthy controls (HC;P< .001), and inmild cognitive impairment (MCI)
compared to HC (P = .008 NfL; P < .001 NfL/A𝛽42). CSF NfL and NfL/A𝛽42 differenti-
ated AD fromHCwith an area under the receiver operating characteristic (ROC) curve
(AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/A𝛽42 predicted cortical amyloid
load, brain atrophy, and cognition.
Discussion: CSF NfL is a biomarker of neurodegeneration, correlating with cognitive
impairment and brain neuropathology.
K EYWORD S
amyloid, biomarker, dementia, diagnosis, ELISA, neurodegeneration, neurofilaments
1 INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia.1 The
use of positron emission tomography (PET) imaging has not only led to
the possibility of diagnosis pre-mortem, but also to the confirmation
that AD pathology developsmany years before the symptoms appear.2
However, PET diagnostic methods have limited utility due to the high
cost and poor accessibility. For more cost-effective diagnostic tools, a
significant amount of research has been done to explore and validate
cerebrospinal fluid (CSF) biomarkers.3 This has led to CSF biomarkers
being included in the diagnostic criteria for AD in 2011, by theNational
Institute on Aging (NIA) and the Alzheimer’s Association (AA),4 and
the International Working Group (IWG) in 2014.5 In addition, blood
biomarkers have been investigated, as well as eye imaging; however,
these approaches although promising require considerably more evi-
dence to be as convincing as the gold standard CSF biomarkers.6–8
Evidence indicates that AD is a disease of multiple etiologies, with
numerous risk factors that overlap with respect to metabolic and
pathological changes they cause, yet together direct and/or acceler-
ate the trajectoryofADdementia.3,9 Themultiplepathological changes
are associated with specific biomolecules that might serve as biomark-
ers formaking a diagnosis, and as indicators of changes that occur with
disease progression.
This article focuses on CSF neurofilament light (NfL) chain pro-
tein and its potential as an AD biomarker. NfL has emerged as one of
the most promising CSF markers of neurodegeneration, for diagnos-
tic purposes, and in particular for studying disease neuropathological
progression.10–14 Elevated CSF NfL levels are linked to white matter
changes in the brain, which reflects the fact that NfL is a biomarker of
axonal degeneration.15 Elevated levels are associated with rate of hip-
pocampal atrophy in cognitively healthy individuals, including those at
risk for AD.16 In addition recent studies have reported elevated levels
of NfL in the plasma of AD subjects.17,18
Neurofilaments are phosphoproteins that are synthesized in the
cell bodies and then translocated to the axons.19 The functions of
neurofilaments depend on their state of phosphorylation.20 They are
hetero-polymeric proteins comprising four subunits: neurofilament
heavy (NfH), neurofilament medium (NfM), and neurofilament light
(NfL) polypeptides and 𝛼-internexin or peripherin.21 Neurofilaments
are found particularly in neuronal axons, keeping themyelinated axons
structurally stable and playing an essential role in the growth and
impulse conduction along the axons.21 They also act as skeletal sup-
ports, helping to maintain the shape of neurons.22 Neuronal damage
in neurodegenerative diseases, as well as in acute brain injury, would
likely result in the release of neurofilaments into the CSF.
The present study aimed to investigate the utility of CSF NfL lev-
els in the diagnosis of AD and in the assessment of brain amyloid load,
atrophy, and cognition. The study was conducted by using baseline
CSF samples fromparticipants in theAustralian Imaging, Biomarkers &
Lifestyle Flagship Study of Ageing (AIBL). The aims of the present study
were as follows: (1) to assess the diagnostic utility of NfL in distinguish-
ing AD from mild cognitive impairment (MCI) and healthy controls
(HCs); (2) to assess the diagnostic accuracy of NfL (alone or in combi-
nation with CSF amyloid 𝛽 [A𝛽42], CSF total tau [T-tau], or phospho-
rylated tau [P-tau]) in differentiating AD from controls using receiver
operating characteristic (ROC) curve analysis; (3) to assess whether
there is an association between CSF NfL levels and amyloid levels, tau
pathology, and/or brain volumes; (4) to assess whether CSF NfL levels
predict baseline brain amyloid load, brain atrophy, and cognition; and
(5) to assess whether NfL predicts change in brain amyloid burden.
2 MATERIALS AND METHODS
2.1 Participants
This study reports on data and samples obtained from221 participants
recruited as a part of the AIBL study (http://aibl.csiro.au/), who had
their CSF collected at baseline between 2009 and 2016. Among these,
100 were recruited at the time of the study inception and the remain-
ing participants were recruited during enrichment of the cohort. The
AIBL is a prospective, longitudinal study that assesses the participants
at 18-month intervals, investigating changes in biomarkers, cognition,
and other parameters. The study was initiated in 2006 to investigate
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potential biomarkers, cognitive parameters, and lifestyle factors
associated with AD. The study consists of individuals categorized as
AD, MCI, and HC.23 The classification of AD is based on the National
Institute of Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria24 and MCI based on the protocol defined
by the criteria given byWinblad et al.,25 which is informed by Petersen
et al. criteria.26 Exclusion criteria include heavy alcohol consumption,
past serious head injury, history of non-AD dementia, current clinical
depression, schizophrenia, bipolar disorder, epilepsy, Parkinson dis-
ease, cancer (other than basal cell skin carcinoma), history of stroke,
untreated obstructive sleep apnea, and withdrawal of consent.23 The
AIBL has been approved by the institutional ethics committees of
Austin Health, St. Vincent’s Health, Hollywood Private Hospital, and
Edith CowanUniversity. All volunteers providedwritten informed con-
sent before participating in the study. The study participants (n = 221)
were clinically classified asHC (n= 159),MCI (n= 34), andAD (n= 28).
Age, gender, and apolipoprotein E (APOE) genotype datawere assessed
as part of the cohort demographic characterization. TheAIBL hasmore
than 2400 participants, and lumber punctures (LPs) have been done on
over 200participants only, because about one in10agreed tohaveone.
2.2 Brain imaging and cognitive assessment
Cognitive assessment was done using a neuropsychological battery
comprising various tests, which cover themain domains of cognition.23
Of interest, in this article were the baseline Mini-Mental State Exam
(MMSE) scores. Most of these participants (n = 195) underwent amy-
loid imaging using positron emission tomography (PET) with differ-
ent tracers (carbon-11 (C-11) labeled Pittsburgh compound B [11C-
PiB], fluorine-18 [F-18] labeled florbetapir or F-18 labeled flutemeta-
mol). Each amyloid tracer has a different dynamic range; therefore, to
place all the standardized uptake value ratios (SUVRs) on the same
continuous scale, the SUVR from the F-18 tracers were transformed
into PiB-like SUVR units as described previously.27 A subgroup of par-
ticipants (n = 118) underwent amyloid imaging at follow-up (average
follow-up interval, 18months). A subgroupof theparticipants (n=179)
underwent brainmagnetic resonance imaging (MRI). Themethodology
for MRI image acquisition, brain segmentation, and volumes has been
described elsewhere.28
2.3 Sample collection and storage
CSF samples were collected by lumbar puncture (LP) in the morn-
ing after overnight fasting. Collection of CSF samples was performed
at two centers (Perth and Melbourne) as per the guidelines rec-
ommended by the Alzheimer’s Biomarker Standardization Initiative
(ABSI).29 Following collection, sampleswere centrifuged and aliquoted
into polypropylene tubes (0.5mL) and stored at−80◦C in a liquid nitro-
gen vapor tank. Prior to NfL analysis, all samples went through one
freeze-thaw cycle to aliquot the samples further.
HIGHLIGHTS
• Cerebrospinal fluid (CSF) neurofilament light (NfL) is a
biomarker of neurodegeneration in Alzheimer’s disease
(AD), the levels of which are significantly elevated in AD
as compared to controls, and distinguish AD from controls
with a high sensitivity of 81.5%.
• CSFNfL significantly predicts cortical graymatter volume
loss at baseline.
• CSF NfL significantly predicts the state of cognition at
baseline.
RESEARCH INCONTEXT
1. Systematic review: Neurofilament light (NfL) has
emerged as one of the most promising cerebrospinal
fluid (CSF) markers of neurodegeneration for the diag-
nosis and study of disease progression in Alzheimer’s
disease (AD). Various studies have highlighted the role of
CSFNfL and plasmaNfL as a potential AD biomarker.
2. Interpretation: To further validate the utility of CSF NfL
as an AD biomarker, its levels were assessed in CSF sam-
ples from the Australian Imaging, Biomarkers & Lifestyle
Flagship Study of Ageing (AIBL). CSF NfL levels were sig-
nificantly elevated in AD and demonstrated a high sensi-
tivity in distinguishing AD from healthy controls (HCs). In
addition, CSF NfL levels predicted baseline cognition and
cortical graymatter volume.
3. Future directions: We further aim to evaluate the utility
of CSF NfL to predict disease onset in HCs that progress
to dementia, aswell as its utility for predicting rate of cog-
nitive decline in individuals with AD.
2.4 Biomarkermeasurement
CSF NfL concentration was quantified using a commercial enzyme-
linked immunosorbent assay (ELISA) (NF-light; UmanDiagnostics,
Umeå, Sweden), according to the manufacturer’s protocol. All samples
were analyzed in duplicate and a pooled control CSF was also run to
check for the interplate variation. The percentage coefficient of vari-
ance (CV) between duplicateswas<8%and between plateswas<12%.
CSFA𝛽42, T-tau, and P-tau concentrationswere also analyzed in dupli-
cate using ELISAs: INNOTEST 𝛽-AMYLOID (1−42) (A𝛽42), INNOTEST
hTAU Ag (T-tau), and INNOTEST PHOSPHO-TAU (181P) (P-tau181P)
(Fujirebio, Ghent, Belgium) according to themanufacturer’s protocol.
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2.5 Statistical analysis
Analysis of covariance (ANCOVA) was used to assess for differences
in at least one pair of continuous mean CSF or brain volumetric mea-
sures between participant groups after adjustments for age, gender
and APOE genotype (presence of 𝜀4 allele). The CSF measures and
brain volumetric measures required natural logarithm transformation
to normalize the distributions for subsequent analysis so that assump-
tionswould bemet. Chi-square testswere used to compare categorical
variables andKruskal-Wallis analysis of variance (ANOVA)was used to
compare groups for MMSE. Bonferroni corrections were made for all
pairwise comparisons. Linear correlations between CSF NfL and other
markers, as well as brain volumetric measures were analyzed by Pear-
son’s product moment correlation, after transforming them using the
natural logarithm. ROC curve analysis was carried out to assess the
diagnostic utility of various CSF markers (untransformed and contin-
uous, ie, raw) for determination of AD versus HC. A cutoff value for the
raw CSF marker was also selected, which provided similar specificity
and sensitivity. Multiple regression analysis was undertaken to assess
the utility of CSF NfL and other CSF measures (CSF A𝛽42, T-tau, P-
tau) including different ratios (NfL/A𝛽42, T-tau/A𝛽42, P-tau/A𝛽42), for
predicting the baseline amyloid load as measured by SUVR, brain atro-
phy (gray matter volume), and cognition (MMSE). A log transformation
was applied to SUVR so that regression assumptions were met. Gray
matter volume did not require transformation to meet assumptions in
these models. MMSE is not normally distributed (it is left skewed) and
transformations are not available that rectify this issue. All biomark-
ers were rescaled to have the same units (ng/mL). Standardized regres-
sion coefficients30 and R2 (ie, the proportion of variability explained
by a model) were used to differentiate the CSF predictors. Similarly,
regression analysis was used to assess the utility of CSF NfL and other
measures to predict change in brain amyloid load, by using log SUVR
at follow-up as the outcome, and log SUVR at baseline and the time
interval between the amyloid scans as additional predictors. All anal-
yses controlled for the covariates: age, gender and apolipoprotein E
(APOE) genotype (presence of 𝜀4 allele). For each of the regression and
ANCOVA models, all variables were entered at the same time in a sin-
gle step. For all regression analyses, assumptions were checked in the
usual way (ie, via histograms of the residuals, scatterplots of the resid-
uals vs fitted values) and deemed reasonable unless otherwise stated.
For all the tests a P value <0.05 was considered statistically signifi-
cant. Statistical analysis was performed using IBMSPSS version 25 (for
MicrosoftWindows).
3 RESULTS
3.1 Diagnostic utility of NfL for distinguishing
different diagnostic groups
Levels of NfL in the CSF samples of the 221 participants were quanti-
fied. Table 1 shows the summary of the demographics and biomarker
data of the participants. Two samples were eliminated from the anal-
ysis owing to their influence in the diagnostic plots even after natu-
ral logarithm transformation of the CSF NfL. Both samples were of
AD-affected participants and had very high values. Therefore, analy-
sis was carried out using the data from the remaining 219 participants,
to assess the differences between any pair of participant groups after
log transformation of the CSF measures. NfL levels were significantly
increased in AD as compared to HC (P < .001), as well as in MCI com-
pared to HC (P= .008). Levels were not significantly different between
theADandMCI groups (Figure 1,P= .139). The ratio of CSFNfL toCSF
A𝛽42 (NfL/A𝛽42), was significantly elevated in AD compared to both
MCI (P = .007) and HC (P < .001). In addition, NfL/A𝛽42 was signifi-
cantly elevated inMCI compared to HC (P< .001). Similar results were
observed for other biomarkers (CSF A𝛽42, T-tau, P-tau) including the
ratios (T-tau/A𝛽42, P-tau/A𝛽42), as shown in Table 1.
ROC curve analyses were undertaken for all 221 samples, to assess
the ability of individual CSFmeasures, as well as different ratios to dif-
ferentiate AD from HC (results shown in Table 2). CSF NfL differenti-
atedAD from controls with an area under the ROC curve (AUC) of 0.84
anda sensitivity and specificity of 81.5%and79.7%, respectively,which
is comparable to the results obtained using CSF A𝛽42, but higher than
thebiomarkers of taupathology (Table 2).NfL/A𝛽42 ratio distinguished
AD from controls, with an AUC of 0.90 and a sensitivity and specificity
of 81.5% and 80.4%, respectively. Among the individual measures, CSF
T-tau had the highest AUC of 0.87 and among the ratios, T-tau/A𝛽42
with an AUC of 0.91.
3.2 Association of NfL with amyloid and tau
pathology
Toassess the association ofNfLwith amyloid pathology (viaCSFA𝛽42),
the extent of correlation between CSF NfL and CSF A𝛽42 (both trans-
formed using natural logarithm) was evaluated. There was no signifi-
cant correlation betweenNfL andCSFA𝛽42 (r=−0.122, P= .072). The
association of NfL with tau pathology was assessed by the extent of
correlation between CSF NfL and CSF T-tau and P-tau after transfor-
mation using natural logarithm. CSF NfL was significantly correlated
with CSF T-tau (r = 0.52, P < .001) and P-tau (r = 0.43, P < .001).
The correlations remained significant even after controlling for age
and gender.
3.3 Association of NfL with brain atrophy
Associations between CSF NfL and brain volumes (cortical gray mat-
ter, white matter, ventricular and hippocampal volumes) were investi-
gated, after transforming to natural logarithm. There was a significant
negative moderate correlation between cortical gray matter volume
and NfL (r = −0.38, P < .001) and a significant weak negative correla-
tion between hippocampal volume and NfL (r = −0.27, P < .001). CSF
NfL levels were not associated significantly with either white matter
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TABLE 1 Summary of demographics and biomarker data at baseline
Participant groups
HC MCI AD
Demographics
Number of participants (n= 221) 159 34 28
GenderM/F (% females) 75/84 (53%) 21/13 (38%) 16/12 (43%)
Age at LP (years) 72.8 (5.54) 74.1(7.62) 74.6 (7.54)
APOE 𝜀4 allele not present/present
(% present)
121/38 (24%) 19/15 (44%)* 11/17 (61%)*
Cognitive scores
MMSE 29 (1.45) 27 (2.15)* 21 (4.95)*,†
CSFmeasures
CSF A𝛽42 (pg/mL) (n= 219) 872 (268.84) 714 (207.44)# 588 (198.41)*,‡
CSF T-tau (pg/mL) (n= 219) 249 (112.98) 334 (177.47)# 488 (252.70)*,¶
CSF P-tau (pg/mL) (n= 219) 54 (18.92) 61 (27.28) 73 (25.78)#
CSFNfL (pg/mL) (n= 219) 1506 (510.59) 1977 (908.44)§ 2201 (626.96)*
T-tau/A𝛽42 (n= 219) 0.31 (0.19) 0.51 (0.31)§ 0.95 (0.69)*,†
P-tau/A𝛽42 (n= 219) 0.07 (0.03) 0.09 (0.05) 0.14 (0.08)*,¶
NfL/A𝛽42 (n= 217) 1.89 (0.87) 2.96 (1.60)* 4.09 (1.82)*,¶
MRI brain volumetric measures (n= 179)
Cortical graymatter volume (cm3) 460.11 (19.47) 446.91 (22.29)# 430.48 (28.35)*,‡
Cortical whitematter volume (cm3) 392.34 (20.17) 391.38 (27.46) 377.50 (24.38)‡ ,#
Ventricular volume (cm3) 35.71 (15.25) 44.16 (21.47) 58.67 (30.69)*,‡
Hippocampal volume (cm3) 2.95 (0.29) 2.77 (0.41) 2.32 (0.52)*,†
AD, Alzheimer’s disease; APOE, apolipoprotein E; A𝛽 , amyloid beta; CSF, cerebrospinal fluid; HC, healthy control; LP, lumbar puncture; MCI, mild cognitive
impairment;MMSE,Mini-Mental State Exam; NfL, neurofilament light; P-tau, phosphorylated tau; T-tau, total tau.
NOTE. The values in the table represent rawmeans (standard deviation, SD) unless otherwise indicated. Demographic and clinical characteristics were com-
pared among the groups using analysis of covariance (ANCOVA) or chi-square tests. CSFmeasures and cortical brain volumetricmeasureswere transformed
using the natural logarithm for ANCOVA analyses, and differences in means were assessed after controlling for age, gender, and APOE genotype. MMSEwas
analyzed using Kruskal-Wallis nonparametric ANOVA.
*P< .001 versus HC.
†P< .001 versusMCI.
‡P< .05 versusMCI.
§P< .01 versus HC.
¶P< .01 versusMCI.
#P< .05 versus HC.
F IGURE 1 Comparison of themeanNfL concentration with 95%
confidence interval, among the study groups AD (n= 26),MCI (n= 34),
HC (n= 159). AD, Alzheimer’s disease; CSF, cerebrospinal fluid; HC,
healthy control; MCI, mild cognitive impairment; NfL, neurofilament
light
volume (r = 0.03, P = .687) or ventricular volume (r = 0.104, P = .166).
Because therewas a significantmoderate correlationbetweenCSFNfL
and cortical graymatter volume, the utility of CSFNfL as a predictor of
baseline graymatter volumewas assessed further.
3.4 Utility of CSFNfL levels as an indicator of
amyloid burden, brain atrophy, and cognition
Individually, each of the CSF biomarkers significantly predicted base-
line amyloid load as measured by log SUVR, brain atrophy (measured
by cortical gray matter volume), as well as baseline cognition (mea-
sured byMMSE), while controlling for covariates in a linear regression
(Table 3). Higher levels of CSF NfL (𝛽 = 0.11, standardized 𝛽 = 0.24,
P = .001) and the larger NfL/A𝛽42 ratio (𝛽 = 0.10, standardized
𝛽 = 0.51, P < .001) were associated with significantly higher baseline
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TABLE 2 ROC curve analysis data for AD versus HC for
continuous CSF variables and ratios
Variable AUC (95%CI) Cutoff Sensitivity Specificity
AD versus HC
CSF A𝛽42
(pg/mL)
0.84 (0.75–0.93) 642 81.5% 82.3%
CSF T-tau
(pg/mL)
0.87 (0.81–0.93) 308 74.1% 75.9%
CSF P-tau
(pg/mL)
0.73 (0.64–0.82) 57 66.7% 63.9%
CSFNfL
(pg/mL)
0.84 (0.76–0.92) 1825 81.5% 79.7%
T-tau/A𝛽42 0.91 (0.85–0.97) 0.47 85.2% 84.8%
P-tau/A𝛽42 0.87 (0.79–0.94) 0.09 81.5% 80.4%
NfL/A𝛽42 0.90 (0.84–0.97) 2.53 81.5% 80.4%
AD, Alzheimer’s disease; AUC, area under the receiver operating charac-
teristic (ROC) curve; A𝛽 , amyloid beta; CI, confidence interval; CSF, cere-
brospinal fluid; HC, healthy control; NfL, neurofilament light; P-tau, phos-
phorylated tau; T-tau, total tau.
NOTE. Cutoffs were determined by keeping specificity and sensitivity
approximately equal. The cutoffs have been rounded to the nearest whole
number forCSFA𝛽42,CSFT-tau,CSFP-tau, andCSFNfL. This analysis used
untransformed (raw) data.
amyloid load even upon controlling for covariates such as age, gender,
and APOE genotype (presence of 𝜀4 allele). Among the individual
CSF measures, CSF A𝛽42 (standardized 𝛽 = −0.53) was the strongest
predictor of baseline amyloid as measured by log SUVR (Table 3),
whereby smaller CSF A𝛽42 values were associated with significantly
higher baseline amyloid loads. The different independent variables
were combined as ratios, to determine whether they could predict
baseline brain amyloid load better when evaluated together. A model
including the ratio of CSF NfL and A𝛽42 accounted for 40% variability
in baseline amyloid load. The models including the ratio of CSF T-tau
or P-tau and CSF A𝛽42 explained more of the variability in baseline
amyloid load (50% and 52%, respectively).
Among the CSF measures, the individual measures and derived
ratios were all significantly associated with predicted baseline brain
volume or brain atrophy, as measured by cortical gray matter volume,
upon controlling for covariates, except CSF P-tau (Table 3). CSF NfL
(𝛽 =−10.15, standardized 𝛽 =−0.29, P< .001) andNfL/A𝛽42 ratio (𝛽 =
−6.99, standardized 𝛽 = −0.43, P < .001) correlated significantly with
smaller baseline cortical gray matter volume. The ratio of CSF NfL and
A𝛽42 levels (R2 = 32%) was a better predictor of cortical brain atrophy
than either of these measures individually. Among the individual mea-
sures, CSF NfL, and among the ratios, NfL/A𝛽42, were the best predic-
tors of brain atrophy.
All CSFmeasures and the ratios derived from thesemeasures signif-
icantly predicted baseline cognition as measured byMMSE, even after
controlling for covariates (Table 3). CSF NfL (𝛽 = −1.06, standardized
𝛽 =−0.25, P< .001) and the ratio ofNfL/A𝛽42 (𝛽 =−0.84, standardized
𝛽 =−0.41, P< .001) were associated significantly with baselineMMSE
scores; however, CSF T-tau (standardized 𝛽 = −0.34) and T-tau/A𝛽42
(standardized 𝛽 =−0.43) were strongerMMSE score predictors. None
TABLE 3 Regression results to estimate the effect of CSF
measures for predicting baseline amyloid load, brain volume/atrophy
(cortical graymatter volume) and baseline cognitive scores
Predictor
Unstandardized
𝜷 (SE)
Standardized
𝜷 R2 P value
Baseline amyloid load (n= 188)
CSFNfL (ng/mL) 0.11 (0.03) 0.24 0.23 0.001
CSF A𝛽42 (ng/mL) −0.56 (0.06) −0.53 0.44 <0.001
CSF T-tau (ng/mL) 0.91 (0.12) 0.46 0.38 <0.001
CSF P-Tau (ng/mL) 5.08 (0.83) 0.39 0.32 <0.001
NfL/A𝛽42 0.10 (0.01) 0.51 0.40 <0.001
T-tau/A𝛽42 0.50 (0.05) 0.58 0.50 <0.001
P-tau/A𝛽42 3.49 (0.31) 0.60 0.52 <0.001
Cortical graymatter volume (n= 176)
CSFNfL (ng/mL) −10.15 (2.56) −0.29 0.24 <0.001
CSF A𝛽42 (ng/mL) 21.75 (5.98) 0.26 0.23 <0.001
CSF T-tau (ng/mL) −29.32 (11.31) −0.19 0.20 0.010
CSF P-Tau (ng/mL) −88.14 (78.27) −.082 0.17 0.262
NfL/A𝛽42 −6.99 (1.11) −0.43 0.32 <0.001
T-tau/A𝛽42 −23.26 (4.72) −0.33 0.27 <0.001
P-tau/A𝛽42 −139.28 (32.53) −0.30 0.25 <0.001
MMSE (n= 214)
CSFNfL (ng/mL) −1.06 (0.29) −0.25 0.13 <0.001
CSF A𝛽42 (ng/mL) 2.51 (0.68) 0.25 0.13 <0.001
CSF T-tau (ng/mL) −6.12 (1.18) −0.34 0.18 <0.001
CSF P-Tau (ng/mL) −26.58 (8.12) −0.22 0.12 0.001
NfL/A𝛽42 −0.84 (0.13) −0.41 0.22 <0.001
T-tau/A𝛽42 −3.61 (0.52) −0.43 0.25 <0.001
P-tau/A𝛽42 −20.86 (3.58) −0.38 0.20 <0.001
A𝛽 , amyloid beta; CSF, cerebrospinal fluid; MMSE, mini-mental state exam-
ination score; NfL, neurofilament light; P-tau, phosphorylated tau; SE, stan-
dard error; T-tau, total tau. Baseline amyloid as measured by SUVR was
transformed using the natural logarithm for regression analyses.
of the predictors explained more than 26% of the variability in MMSE
scores. Because MMSE scores are left skewed, no simple transforma-
tion can be used to normalize the scores. As such, the assumption of
normality of the errors was not met and the results should be treated
with caution.
3.5 Utility of baseline CSFNfL to predict change in
amyloid accumulation
Baseline CSF NfL was not associated significantly with the change in
amyloid accumulation as measured by log SUVR (𝛽 = −0.02, standard-
ized 𝛽 = −0.04, P = .166). Similar results were obtained for other indi-
vidual CSF measures (Table 4). Among the ratios, only the ratio of
baseline-measured P-tau/A𝛽42 was associated with change in amyloid
accumulation (𝛽 = 0.58, standardized 𝛽 = 0.08, P= .036).
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TABLE 4 Regression results to estimate the effect of baseline CSF
measures for predicting change in amyloid accumulation as measured
by log SUVR
Predictor (n= 118)
Unstandardized
𝜷 (SE)
Standardized
𝜷 P value
CSFNfL (ng/mL) −0.02 (0.01) −0.04 0.166
CSF A𝛽42 (ng/mL) −0.04 (0.03) −0.04 0.218
CSF T-tau (ng/mL) 0.04 (0.06) 0.02 0.523
CSF P-Tau (ng/mL) 0.40 (0.38) 0.03 0.283
NfL/A𝛽42 −0.01 (0.01) −0.02 0.505
T-tau/A𝛽42 0.06 (0.04) 0.05 0.173
P-tau/A𝛽42 0.58 (0.27) 0.08 0.036
A𝛽 , amyloid beta; CSF, cerebrospinal fluid; NfL, neurofilament light; P-tau,
phosphorylated tau; SE, standard error; T-tau, total tau.
4 DISCUSSION
Consistent with findings from other studies, the current study shows
that CSF NfL is a promising biomarker of AD-related neurodegen-
eration, demonstrating it is potentially useful in both AD diagno-
sis and for studying the disease’s preclinical stages of pathogenic
progression.10,13,14,31 CSF NfL levels were significantly higher in AD
patients as compared toHCs.Moreover,NfL distinguishedAD fromHC
with reasonably high sensitivity and specificity. As seen in Table 2, the
AUCofNfL can distinguish AD fromHC as effectively as T-tau andCSF
A𝛽42, and it can distinguish AD from HC with higher AUC than P-tau
levels. CSF NfL levels correlated significantly with the biomarkers of
tau pathology, as well as baseline cortical gray matter volume and hip-
pocampal volume. Baseline NfL levels significantly predicted baseline
cortical gray matter volume and cognitive scores. NfL/A𝛽42 was the
best predictor of brain atrophy and was among the best predictors of
cognitive scores. These results indicate that CSFNfL levels can be used
in the assessment of cognitive decline, brain atrophy, and the stage of
neurodegeneration along the disease trajectory.
There was little correlation found between CSF NfL and CSF A𝛽42
levels. CSF NfL was a significant but weaker predictor of baseline
amyloid load and did not predict longitudinal change in amyloid accu-
mulation. This implies that CSF NfL levels are more likely reflective
of neurodegeneration and brain atrophy than the developing amyloid
pathology. Nevertheless, the ratio of CSF NfL/A𝛽42 had a much higher
diagnostic accuracy in distinguishing patients with AD from controls.
This highlights the fact that although developing amyloid pathology
and levels of axonal degeneration correlate with each other to a
lesser extent than some of the other variables tested here, the two
pathologies were found to develop concurrently along the disease
trajectory in our cohort.
In a recent study of mouse models of neurodegenerative diseases,
both CSF and plasma NfL levels increased with the onset and pro-
gression of proteopathic lesions in the brain.32 These increases were
seen in the models of several neurodegenerative conditions, including
𝛼-synucleinopathies, tauopathies, and amyloidoses such as AD. The
CSF NfL levels were elevated in the mice before neurological signs
of neurodegeneration were evident, supporting the concept that NfL
changes occur early in the disease process and can act as a preclinical
disease biomarker.32 The study also showed that the increases in
CSF NfL levels normally found in an AD mouse model (APPPS1) were
much lower following 6 months of treatment with a 𝛽-secretase 1
(BACE1) inhibitor, indicating that NfL levels might be useful as a
treatment response biomarker.32 Therefore, NfL could be used as a
preclinical marker of neurodegeneration (axonal degeneration), and in
conjunction with the biomarkers of tau and amyloid pathology could
provide specific disease diagnosis. The lack of significant difference in
NfL levels between MCI and AD patients suggest that axonal degen-
eration is too compromised following the onset of clinical symptoms,
and further studies will determine if the range of CSF NfL levels
seen within the MCI group of patients reflects neurodegeneration
stage.
NfL is a non-specific marker of axonal degeneration elevated in a
range of neurodegenerative and neurological disorders such as synu-
cleinopathies, amyotrophic lateral sclerosis,33 frontotemporal demen-
tia (FTD),34 Creutzfeldt-Jakob disease,35 and vascular dementia.36
However, studies have shown that the levels vary between different
disorders,36–38 and further studies will evaluate the potential of NfL
as a marker in differential diagnosis, when used in combination with
disease-specific biomarkers, such as A𝛽42. Being a non-specific neu-
rodegeneration marker, it is not associated with amyloid accumula-
tion. Of interest, CSF NfL levels seem to reflect the intensity of axonal
degeneration in all neurodegenerative conditions, as reflected in cogni-
tion scores,31 thus disease-specific research into the value of CSF NfL
levels will determine the value of using this biomarker in other neu-
rodegenerative conditions.
It can be concluded that CSF NfL, as a biomarker of neurodegen-
eration in AD, is of similar sensitivity to CSF A𝛽42 and tau biomark-
ers. However, CSF NfL should be used in combination with these more
disease-specific biomarkers, as it is a general biomarker of neurode-
generation and not specific to any particular neurodegenerative dis-
ease. NfL predicts cortical graymatter volume loss, as well as cognitive
impairment. Therefore, NfL can be used as amarker of neurodegenera-
tion that associateswith cognitive impairment and brain atrophy, along
the disease trajectory. It could serve as a better predictor of disease
progression, as a surrogate marker of neurodegenerative changes, in
clinical trials.
Recent studies suggest that plasma NfL levels are of diagnostic
value in AD, and to a greater extent than in other conditions, such as
Parkinson disease.39 In familial AD cases, serum NfL levels have been
shown to increase at preclinical stages, correlating with measures of
disease stage and severity,40 with more recent longitudinal studies by
the same research group indicating serum NfL starts to increase more
than a decade before symptom onset in familial AD cases.41 How-
ever, blood NfL is thought to originate from the CSF, and blood lev-
els of NfL correlate well with levels seen in the CSF, although they
rise to a lesser extent and later than in the CSF.32 These studies are
encouraging; however, studies are still needed to evaluate the diagnos-
tic value of both blood and CSF levels of NfL in preclinical sporadic AD
cases.
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